Career Development Award
*NEW 'Letter of Intent' Deadline: Thursday, October 15, 2015
*NEW Application Deadline: Tuesday, December 8, 2015
Award Start Date: January 1, 2016
The National Hemophilia Foundation (NHF), a nonprofit organization founded in 1948, is dedicated to finding better treatments and cures for inheritable bleeding disorders and to preventing the complications of these disorders through education, advocacy, and research. NHF seeks research grant applications from established investigators, preferably at the assistant professor level or above, who have demonstrated a commitment to bleeding disorders research. We especially encourage innovative projects that promote the development of novel technologies and/or therapies to advance the field of bleeding disorders research.
The funding for this award has been made possible by a generous grant from Novo Nordisk, Inc.
Candidates must hold an MD, PhD, or equivalent degree, with no more than six years of postdoctoral years of experience in hematology, nor more than six years since completion of medical training. United States citizenship is not required, but applicants must be affiliated with or be faculty members of a U.S.-based domestic organization, such as - universities, colleges, hospitals or laboratories. Only non-commercial institutions and investigators associated with a non-commercial institution are eligible to apply for this award.
The CDA award recipient will be expected to spend at least 75% of their working time on the funded research project. The CDA recipient and his/her mentor are also expected to remain at their institution for the duration of the project. For the application, letters of support from appropriate institutional officials (department chair and financial grants officer) indicating the institution’s commitment to allow the candidate to focus his/her efforts on the stated research project will be required.
Scope of Research
NHF is interested in funding innovative research studies in the area of bleeding disorders to be carried out at the sub cellular, cellular, animal or human/patient levels.
Studies to evaluate the genetic and immunologic bases for inhibitor development may lead to strategies to circumvent this potential complication of clotting factor replacement and/or gene transfer. This research could provide the opportunity to determine the prognostic indicators that place patients at risk of inhibitor development. Inhibitor research may also lead to the development of synthetic replacement factor and gene therapy products with decreased immunogenicity. This includes research on genotype/phenotype relationships and susceptibility to inhibitors.
Better functional assays for clotting factor proteins are also needed. Reproducible, low-volume measure of factor VIII and factor IX activity in different animal models would greatly facilitate validation of in vivo gene therapy studies as well as innovative alternative treatment strategies. Structural studies of clotting factor proteins are needed in order to design more efficacious, longer-lived clotting factor proteins. Development of both small, biologically active, orally delivered molecules and improved protein delivery systems represent strategies that could lead to advances in our understanding of bleeding disorders.
While gene therapy has been an approach which has shown much promise, no one method has been demonstrated to be superior. Multiple experimental strategies may be undertaken to help find a “cure” for bleeding disorders. NHF is seeking research proposals on the nature, propagation, and use of hematopoietic, liver, or stem cells as an approach for gene transfer for hemophilia or other novel approaches for treating bleeding disorders. All CDA research proposals are subjected to a rigorous peer review process. Applications will be reviewed on scientific merit and scored in terms of project significance, scientific approach, innovation, investigator qualifications and institutional environment.
All interested candidates need to submit a ‘Letter of Intent’ by no later than 5 pm ET on Thursday, October 15, 2015. Letters that do not arrive by 5pm Eastern on the deadline date will not be accepted.
LOIs will be evaluated by members of NHF’s Research Review Committee who will collectively decide upon those candidates invited to submit a CDA application. Upon receiving LOI approval, candidates will have until December 8, 2015 to submit their full CDA application to NHF.
LOIs should be emailed to Angelina Wang at email@example.com or sent to her attention at NHF, 7 Penn Plaza, 370 7th Avenue, Suite 1204, New York, NY 10001.
LOIs need to be submitted on institutional letterhead and will not be considered for review unless signed by the candidate. LOIs can be addressed to "Members of NHF's Research Review Committee". Letters should be 1 to 1.5 pages in length and include a brief introduction of the candidate-researcher, his/her mentor, institution and a description of the proposed research project. LOIs must also be accompanied by a CV (NIH-style biosketch preferred) for both the candidate as his/her mentor.
(If sending by mail, you will be responsible for allowing for adequate time for postal delivery.)